|
|
|
Volumn 4, Issue 5, 2003, Pages 519-521
|
|
Integrated assessment of preclinical data: Shifting high attrition rates to earlier phase drug development
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFLAMMATORY AGENT;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CALCIPOTRIOL;
CORTICOSTEROID;
CP 76593;
ETANERCEPT;
INFLIXIMAB;
INTERLEUKIN 8;
INTERLEUKIN 8 ANTAGONIST;
INTERLEUKIN 8 ANTIBODY;
LEUKOTRIENE B4;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
LIPOXYGENASE INHIBITOR;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY ABX IL8;
PENTOXIFYLLINE;
PHOSPHODIESTERASE IV INHIBITOR;
PICLAMILAST;
R 6815;
ROLIPRAM;
THEOPHYLLINE;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNCLASSIFIED DRUG;
ASTHMA;
ATOPIC DERMATITIS;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG PENETRATION;
DRUG POTENCY;
DRUG RESEARCH;
DRUG TARGETING;
EDITORIAL;
HUMAN;
MEDICAL DECISION MAKING;
PSORIASIS;
TREATMENT FAILURE;
ANIMALS;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 0037504192
PISSN: 14724472
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|
